Causal relationship between novel antidiabetic drugs and ischemic stroke: a drug-targeted Mendelian randomization study
The escalating global economic burden of ischemic stroke poses a significant public health challenge amid global aging trends. The broad therapeutic efficacy of new antidiabetic drugs may offer new options in the prevention and treatment of ischemic stroke. Consistent conclusions regarding the relat...
Saved in:
| Published in | Frontiers in cardiovascular medicine Vol. 11; p. 1449185 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
Frontiers Media S.A
24.09.2024
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The escalating global economic burden of ischemic stroke poses a significant public health challenge amid global aging trends. The broad therapeutic efficacy of new antidiabetic drugs may offer new options in the prevention and treatment of ischemic stroke. Consistent conclusions regarding the relationship between novel antidiabetic agents and the risk of ischemic stroke remain elusive, and the causal relationship deserves further investigation.
Three novel antidiabetic drug targets were selected, and cis-expression quantitative trait loci (cis-eQTL) were screened as instrumental variables. Genetic association data for ischemic stroke were obtained from the Genome-wide Association Study (GWAS) database. Mendelian randomization (MR) analysis, facilitated by R software, calculated MR estimates for each single nucleotide polymorphism (SNP), and meta-analysis was performed using five methods. To ensure robustness, sensitivity analyses, heterogeneity analyses, horizontal pleiotropy analyses, and co-localization analyses were conducted for significant MR associations.
Three eQTLs for antidiabetic drug genes served as instrumental variables, utilizing a GWAS dataset comprising 34,217 cases and 406,111 controls for ischemic stroke. Genetic variants in glucagon-like peptide-1 receptor agonists (GLP-1 RA) targets exhibited a positive correlation with ischemic stroke risk (OR 1.06, 95% CI 1.04-1.08,
= 0.000), while genetic variation in dipeptidyl peptidase 4 inhibitors (DPP-4i) targets showed a negative association with ischemic stroke risk (OR 0.93, 95% CI 0.89-0.97,
= 0.003). Sensitivity analyses supported robust conclusions, revealing no heterogeneity or horizontal pleiotropy.
This study found that GLP-1 RA and DPP-4i were associated with an increased risk of ischemic stroke by MR analysis. Although sensitivity analyses provide support for this result, it contradicts previous knowledge. Therefore, the results of this study still need to treated with caution. Updated and more in-depth GWAS data and high-quality real-world data are expected to validate the results. |
|---|---|
| AbstractList | The escalating global economic burden of ischemic stroke poses a significant public health challenge amid global aging trends. The broad therapeutic efficacy of new antidiabetic drugs may offer new options in the prevention and treatment of ischemic stroke. Consistent conclusions regarding the relationship between novel antidiabetic agents and the risk of ischemic stroke remain elusive, and the causal relationship deserves further investigation.BackgroundThe escalating global economic burden of ischemic stroke poses a significant public health challenge amid global aging trends. The broad therapeutic efficacy of new antidiabetic drugs may offer new options in the prevention and treatment of ischemic stroke. Consistent conclusions regarding the relationship between novel antidiabetic agents and the risk of ischemic stroke remain elusive, and the causal relationship deserves further investigation.Three novel antidiabetic drug targets were selected, and cis-expression quantitative trait loci (cis-eQTL) were screened as instrumental variables. Genetic association data for ischemic stroke were obtained from the Genome-wide Association Study (GWAS) database. Mendelian randomization (MR) analysis, facilitated by R software, calculated MR estimates for each single nucleotide polymorphism (SNP), and meta-analysis was performed using five methods. To ensure robustness, sensitivity analyses, heterogeneity analyses, horizontal pleiotropy analyses, and co-localization analyses were conducted for significant MR associations.Materials and methodsThree novel antidiabetic drug targets were selected, and cis-expression quantitative trait loci (cis-eQTL) were screened as instrumental variables. Genetic association data for ischemic stroke were obtained from the Genome-wide Association Study (GWAS) database. Mendelian randomization (MR) analysis, facilitated by R software, calculated MR estimates for each single nucleotide polymorphism (SNP), and meta-analysis was performed using five methods. To ensure robustness, sensitivity analyses, heterogeneity analyses, horizontal pleiotropy analyses, and co-localization analyses were conducted for significant MR associations.Three eQTLs for antidiabetic drug genes served as instrumental variables, utilizing a GWAS dataset comprising 34,217 cases and 406,111 controls for ischemic stroke. Genetic variants in glucagon-like peptide-1 receptor agonists (GLP-1 RA) targets exhibited a positive correlation with ischemic stroke risk (OR 1.06, 95% CI 1.04-1.08, P = 0.000), while genetic variation in dipeptidyl peptidase 4 inhibitors (DPP-4i) targets showed a negative association with ischemic stroke risk (OR 0.93, 95% CI 0.89-0.97, P = 0.003). Sensitivity analyses supported robust conclusions, revealing no heterogeneity or horizontal pleiotropy.ResultsThree eQTLs for antidiabetic drug genes served as instrumental variables, utilizing a GWAS dataset comprising 34,217 cases and 406,111 controls for ischemic stroke. Genetic variants in glucagon-like peptide-1 receptor agonists (GLP-1 RA) targets exhibited a positive correlation with ischemic stroke risk (OR 1.06, 95% CI 1.04-1.08, P = 0.000), while genetic variation in dipeptidyl peptidase 4 inhibitors (DPP-4i) targets showed a negative association with ischemic stroke risk (OR 0.93, 95% CI 0.89-0.97, P = 0.003). Sensitivity analyses supported robust conclusions, revealing no heterogeneity or horizontal pleiotropy.This study found that GLP-1 RA and DPP-4i were associated with an increased risk of ischemic stroke by MR analysis. Although sensitivity analyses provide support for this result, it contradicts previous knowledge. Therefore, the results of this study still need to treated with caution. Updated and more in-depth GWAS data and high-quality real-world data are expected to validate the results.ConclusionThis study found that GLP-1 RA and DPP-4i were associated with an increased risk of ischemic stroke by MR analysis. Although sensitivity analyses provide support for this result, it contradicts previous knowledge. Therefore, the results of this study still need to treated with caution. Updated and more in-depth GWAS data and high-quality real-world data are expected to validate the results. The escalating global economic burden of ischemic stroke poses a significant public health challenge amid global aging trends. The broad therapeutic efficacy of new antidiabetic drugs may offer new options in the prevention and treatment of ischemic stroke. Consistent conclusions regarding the relationship between novel antidiabetic agents and the risk of ischemic stroke remain elusive, and the causal relationship deserves further investigation. Three novel antidiabetic drug targets were selected, and cis-expression quantitative trait loci (cis-eQTL) were screened as instrumental variables. Genetic association data for ischemic stroke were obtained from the Genome-wide Association Study (GWAS) database. Mendelian randomization (MR) analysis, facilitated by R software, calculated MR estimates for each single nucleotide polymorphism (SNP), and meta-analysis was performed using five methods. To ensure robustness, sensitivity analyses, heterogeneity analyses, horizontal pleiotropy analyses, and co-localization analyses were conducted for significant MR associations. Three eQTLs for antidiabetic drug genes served as instrumental variables, utilizing a GWAS dataset comprising 34,217 cases and 406,111 controls for ischemic stroke. Genetic variants in glucagon-like peptide-1 receptor agonists (GLP-1 RA) targets exhibited a positive correlation with ischemic stroke risk (OR 1.06, 95% CI 1.04-1.08, = 0.000), while genetic variation in dipeptidyl peptidase 4 inhibitors (DPP-4i) targets showed a negative association with ischemic stroke risk (OR 0.93, 95% CI 0.89-0.97, = 0.003). Sensitivity analyses supported robust conclusions, revealing no heterogeneity or horizontal pleiotropy. This study found that GLP-1 RA and DPP-4i were associated with an increased risk of ischemic stroke by MR analysis. Although sensitivity analyses provide support for this result, it contradicts previous knowledge. Therefore, the results of this study still need to treated with caution. Updated and more in-depth GWAS data and high-quality real-world data are expected to validate the results. Background The escalating global economic burden of ischemic stroke poses a significant public health challenge amid global aging trends. The broad therapeutic efficacy of new antidiabetic drugs may offer new options in the prevention and treatment of ischemic stroke. Consistent conclusions regarding the relationship between novel antidiabetic agents and the risk of ischemic stroke remain elusive, and the causal relationship deserves further investigation. Materials and methods Three novel antidiabetic drug targets were selected, and cis-expression quantitative trait loci (cis-eQTL) were screened as instrumental variables. Genetic association data for ischemic stroke were obtained from the Genome-wide Association Study (GWAS) database. Mendelian randomization (MR) analysis, facilitated by R software, calculated MR estimates for each single nucleotide polymorphism (SNP), and meta-analysis was performed using five methods. To ensure robustness, sensitivity analyses, heterogeneity analyses, horizontal pleiotropy analyses, and co-localization analyses were conducted for significant MR associations. Results Three eQTLs for antidiabetic drug genes served as instrumental variables, utilizing a GWAS dataset comprising 34,217 cases and 406,111 controls for ischemic stroke. Genetic variants in glucagon-like peptide-1 receptor agonists (GLP-1 RA) targets exhibited a positive correlation with ischemic stroke risk (OR 1.06, 95% CI 1.04–1.08, P = 0.000), while genetic variation in dipeptidyl peptidase 4 inhibitors (DPP-4i) targets showed a negative association with ischemic stroke risk (OR 0.93, 95% CI 0.89–0.97, P = 0.003). Sensitivity analyses supported robust conclusions, revealing no heterogeneity or horizontal pleiotropy. Conclusion This study found that GLP-1 RA and DPP-4i were associated with an increased risk of ischemic stroke by MR analysis. Although sensitivity analyses provide support for this result, it contradicts previous knowledge. Therefore, the results of this study still need to treated with caution. Updated and more in-depth GWAS data and high-quality real-world data are expected to validate the results. BackgroundThe escalating global economic burden of ischemic stroke poses a significant public health challenge amid global aging trends. The broad therapeutic efficacy of new antidiabetic drugs may offer new options in the prevention and treatment of ischemic stroke. Consistent conclusions regarding the relationship between novel antidiabetic agents and the risk of ischemic stroke remain elusive, and the causal relationship deserves further investigation.Materials and methodsThree novel antidiabetic drug targets were selected, and cis-expression quantitative trait loci (cis-eQTL) were screened as instrumental variables. Genetic association data for ischemic stroke were obtained from the Genome-wide Association Study (GWAS) database. Mendelian randomization (MR) analysis, facilitated by R software, calculated MR estimates for each single nucleotide polymorphism (SNP), and meta-analysis was performed using five methods. To ensure robustness, sensitivity analyses, heterogeneity analyses, horizontal pleiotropy analyses, and co-localization analyses were conducted for significant MR associations.ResultsThree eQTLs for antidiabetic drug genes served as instrumental variables, utilizing a GWAS dataset comprising 34,217 cases and 406,111 controls for ischemic stroke. Genetic variants in glucagon-like peptide-1 receptor agonists (GLP-1 RA) targets exhibited a positive correlation with ischemic stroke risk (OR 1.06, 95% CI 1.04–1.08, P = 0.000), while genetic variation in dipeptidyl peptidase 4 inhibitors (DPP-4i) targets showed a negative association with ischemic stroke risk (OR 0.93, 95% CI 0.89–0.97, P = 0.003). Sensitivity analyses supported robust conclusions, revealing no heterogeneity or horizontal pleiotropy.ConclusionThis study found that GLP-1 RA and DPP-4i were associated with an increased risk of ischemic stroke by MR analysis. Although sensitivity analyses provide support for this result, it contradicts previous knowledge. Therefore, the results of this study still need to treated with caution. Updated and more in-depth GWAS data and high-quality real-world data are expected to validate the results. |
| Author | Yu, Zongliang Gao, Rui Feng, Xue Zhang, Xiaonan Liu, Xinyi |
| AuthorAffiliation | 1 Beijing University of Chinese Medicine , Beijing , China 2 Xiyuan Hospital, China Academy of Chinese Medical Sciences , Beijing , China |
| AuthorAffiliation_xml | – name: 2 Xiyuan Hospital, China Academy of Chinese Medical Sciences , Beijing , China – name: 1 Beijing University of Chinese Medicine , Beijing , China |
| Author_xml | – sequence: 1 givenname: Zongliang surname: Yu fullname: Yu, Zongliang organization: Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China – sequence: 2 givenname: Xinyi surname: Liu fullname: Liu, Xinyi organization: Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China – sequence: 3 givenname: Xue surname: Feng fullname: Feng, Xue organization: Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China – sequence: 4 givenname: Xiaonan surname: Zhang fullname: Zhang, Xiaonan organization: Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China – sequence: 5 givenname: Rui surname: Gao fullname: Gao, Rui organization: Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39380626$$D View this record in MEDLINE/PubMed |
| BookMark | eNpVUstu1DAUtVARLaUfwAZlySaDX3FsNgiNeFQqYgMSO-smvjPjktiDnUxVvh7Pg6pd2Tr33HNf5yU5CzEgIa8ZXQihzbtVvxsXnHK5YFIapptn5IJz09a0aX6dPfqfk6ucbymlrJG6UfoFORdGaKq4uiB3S5gzDFXCASYfQ974bdXhdIcYqhB3OFQQJu88FND3lUvzOhfIVT73GxwLlKcUf-P7Cg7BeoK0xgld9Q2Dw8FDqFLhx9H_PVQo_NndvyLPVzBkvDq9l-Tn508_ll_rm-9frpcfb-qeG8Pq1nHhEFnbicYxXfpuOS3D6o41TGlKdUc5aKcarrlU6IB1nVsxqVa0kZ0Rl-T6qOsi3Npt8iOkexvB2wMQ09pCKoMNaKnRqlXA-s4oWTZsygYNAFetBiZaUbQ-HLW2czei6zFMCYYnok8jwW_sOu4sY7LRksmi8PakkOKfGfNkx7JGHAYIGOdsxZ5ZLtWyQmVHap9izglXD3UYtXsD2L0B7N4A9mSAkvPmcYMPGf_PLf4BHoWvfw |
| Cites_doi | 10.1007/s00415-019-09601-9 10.1016/s1474-4422(19)30034-1 10.1093/ije/dyv080 10.1136/bmj.l6983 10.1007/s40471-017-0128-6 10.1093/ije/dyy258 10.1681/asn.2016050510 10.1016/j.ajhg.2022.04.001 10.1093/nar/gkad1004 10.1161/strokeaha.122.040073 10.1001/jama.2019.9346 10.1161/strokeaha.119.027557 10.1016/s2468-2667(21)00230-9 10.1212/wnl.0000000000201467 10.1016/j.molmet.2020.101102 10.1093/nar/gkx1037 10.2337/dc21-1993 10.1038/s41588-021-00913-z 10.1161/circresaha.121.319948 10.1093/hmg/ddu328 10.1007/s12035-024-04411-1 10.7326/j22-0003 10.1097/js9.0000000000001926 10.1016/s0140-6736(18)32261-x 10.1002/med.21817 10.1186/s12933-023-01789-5 10.1161/strokeaha.120.031623 10.1038/s41588-018-0058-3 10.3390/cells12182221 10.1016/j.ajhg.2020.11.012 10.1038/s41467-020-16969-0 10.1002/gepi.21965 10.1073/pnas.2319811121 10.1093/eurheartj/ehad736 10.1007/s10654-015-0011-z 10.7326/m15-0308 10.1111/jth.15154 10.1056/NEJMoa1307684 10.1001/jamacardio.2019.2202 10.1056/NEJMoa1509225 10.1038/s41588-023-01529-1 10.3389/fimmu.2023.1232981 10.1371/journal.pgen.1004383 10.1038/s41588-019-0350-x 10.1186/s12933-022-01510-y 10.1093/ije/dyx102 10.1038/s41598-021-94945-4 10.1016/s0140-6736(21)00536-5 10.1038/s41588-018-0099-7 10.1161/circulationaha.123.064346 10.1038/nrneph.2016.170 10.2337/dc23-0671 10.1186/s12967-023-04565-x 10.3389/fcvm.2022.966708 |
| ContentType | Journal Article |
| Copyright | 2024 Yu, Liu, Feng, Zhang and Gao. 2024 Yu, Liu, Feng, Zhang and Gao. 2024 Yu, Liu, Feng, Zhang and Gao |
| Copyright_xml | – notice: 2024 Yu, Liu, Feng, Zhang and Gao. – notice: 2024 Yu, Liu, Feng, Zhang and Gao. 2024 Yu, Liu, Feng, Zhang and Gao |
| DBID | NPM AAYXX CITATION 7X8 5PM DOA |
| DOI | 10.3389/fcvm.2024.1449185 |
| DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2297-055X |
| ExternalDocumentID | oai_doaj_org_article_098676a1cb96438992299aa2678a1373 10_3389_fcvm_2024_1449185 39380626 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Science and Technology Innovation Project of China Academy of Chinese Medical Sciences grantid: CI2021A04701 – fundername: National Key R&D Program of China grantid: 2021YFF0901404 |
| GroupedDBID | 53G 5VS 9T4 AAFWJ ACGFS ACXDI ADBBV ADRAZ ALMA_UNASSIGNED_HOLDINGS AOIJS BCNDV GROUPED_DOAJ HYE IAO IEA IHR IHW IPNFZ KQ8 M48 M~E NPM OK1 PGMZT RIG RPM AAYXX AFPKN CITATION 7X8 5PM |
| ID | FETCH-LOGICAL-c2991-7d23dee17b35d183937209188b15168008b02a8d6528246eda1bbdf146f054b93 |
| IEDL.DBID | RPM |
| ISSN | 2297-055X |
| IngestDate | Mon Sep 30 19:22:41 EDT 2024 Wed Oct 09 05:32:51 EDT 2024 Thu Oct 10 23:52:21 EDT 2024 Wed Sep 25 14:02:47 EDT 2024 Tue Oct 15 08:40:49 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Mendelian randomization analysis SGLT-2 inhibitors DPP-4 inhibitors GLP-1 receptor agonists ischemic stroke novel antidiabetic agents |
| Language | English |
| License | 2024 Yu, Liu, Feng, Zhang and Gao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c2991-7d23dee17b35d183937209188b15168008b02a8d6528246eda1bbdf146f054b93 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Reviewed by: Rania Abdellatif, Minia University, Egypt Edited by: Qianman Peng, Harvard Medical School and Boston, United States Lingli Sun, Peking University, China |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11458414/ |
| PMID | 39380626 |
| PQID | 3114500071 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_098676a1cb96438992299aa2678a1373 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11458414 proquest_miscellaneous_3114500071 crossref_primary_10_3389_fcvm_2024_1449185 pubmed_primary_39380626 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-09-24 |
| PublicationDateYYYYMMDD | 2024-09-24 |
| PublicationDate_xml | – month: 09 year: 2024 text: 2024-09-24 day: 24 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in cardiovascular medicine |
| PublicationTitleAlternate | Front Cardiovasc Med |
| PublicationYear | 2024 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Zhou (B33) 2024 Brown (B12) 2021; 398 Nauck (B36) 2021; 46 Hukku (B48) 2021; 108 Xu (B23) 2024 Larsson (B24) 2023; 44 Zhu (B42) 2023; 21 (B4) 2019; 18 Packer (B49) 2023; 148 Scirica (B41) 2013; 369 Zdrazil (B18) 2024; 52 Lin (B52) 2022; 9 Zhang (B3) 2023; 100 Malik (B22) 2018; 50 Bellastella (B37) 2020; 51 Nazarzadeh (B27) 2019; 4 Broocks (B8) 2020; 267 Davey Smith (B44) 2014; 23 Burgess (B29) 2015; 30 Tuo (B6) 2022; 42 Zhou (B15) 2021; 52 Schmidt (B43) 2020; 11 Pfeffer (B39) 2015; 373 Hernandez (B38) 2018; 392 Shim (B53) 2023; 12 Tsai (B14) 2023; 22 Hartwig (B28) 2017; 46 Li (B19) 2024; 121 Võsa (B21) 2021; 53 Zheng (B45) 2017; 4 Sanna (B25) 2019; 51 Tsai (B54) 2021; 11 Bowden (B31) 2016; 40 Giambartolomei (B47) 2014; 10 Li (B26) 2023; 14 Owolabi (B7) 2022; 7 Wishart (B17) 2018; 46 Yang (B16) 2022; 45 DeFronzo (B11) 2017; 13 Phipps (B1) 2020; 368 Wang (B9) 2022; 21 Xiong (B5) 2022; 130 Kutz (B51) 2023; 46 Zuber (B46) 2022; 109 Kelsey (B13) 2022; 175 Bowden (B34) 2019; 48 Johnston (B10) 2019; 322 Denorme (B35) 2021; 19 Bowden (B30) 2015; 44 Pu (B2) 2023; 54 Verbanck (B32) 2018; 50 Ou (B40) 2015; 163 Ghezzi (B50) 2017; 28 Mostafavi (B20) 2023; 55 |
| References_xml | – volume: 267 start-page: 440 year: 2020 ident: B8 article-title: Elevated blood glucose is associated with aggravated brain edema in acute stroke publication-title: J Neurol doi: 10.1007/s00415-019-09601-9 contributor: fullname: Broocks – volume: 18 start-page: 439 year: 2019 ident: B4 article-title: Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the global burden of disease study 2016 publication-title: Lancet Neurol doi: 10.1016/s1474-4422(19)30034-1 – volume: 44 start-page: 512 year: 2015 ident: B30 article-title: Mendelian Randomization with invalid instruments: effect estimation and bias detection through egger regression publication-title: Int J Epidemiol doi: 10.1093/ije/dyv080 contributor: fullname: Bowden – volume: 368 start-page: l6983 year: 2020 ident: B1 article-title: Management of acute ischemic stroke publication-title: Br Med J doi: 10.1136/bmj.l6983 contributor: fullname: Phipps – volume: 4 start-page: 330 year: 2017 ident: B45 article-title: Recent developments in Mendelian randomization studies publication-title: Curr Epidemiol Rep doi: 10.1007/s40471-017-0128-6 contributor: fullname: Zheng – volume: 48 start-page: 728 year: 2019 ident: B34 article-title: Improving the accuracy of two-sample summary-data Mendelian randomization: moving beyond the nome assumption publication-title: Int J Epidemiol doi: 10.1093/ije/dyy258 contributor: fullname: Bowden – volume: 28 start-page: 802 year: 2017 ident: B50 article-title: Dapagliflozin binds specifically to sodium-glucose cotransporter 2 in the proximal renal tubule publication-title: J Am Soc Nephrol doi: 10.1681/asn.2016050510 contributor: fullname: Ghezzi – volume: 109 start-page: 767 year: 2022 ident: B46 article-title: Combining evidence from Mendelian randomization and colocalization: review and comparison of approaches publication-title: Am J Hum Genet doi: 10.1016/j.ajhg.2022.04.001 contributor: fullname: Zuber – volume: 52 start-page: D1180 year: 2024 ident: B18 article-title: The chembl database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods publication-title: Nucleic Acids Res doi: 10.1093/nar/gkad1004 contributor: fullname: Zdrazil – volume: 54 start-page: 1330 year: 2023 ident: B2 article-title: Projected global trends in ischemic stroke incidence, deaths and disability-adjusted life years from 2020 to 2030 publication-title: Stroke doi: 10.1161/strokeaha.122.040073 contributor: fullname: Pu – volume: 322 start-page: 326 year: 2019 ident: B10 article-title: Intensive vs standard treatment of hyperglycemia and functional outcome in patients with acute ischemic stroke: the shine randomized clinical trial publication-title: Jama doi: 10.1001/jama.2019.9346 contributor: fullname: Johnston – volume: 51 start-page: 666 year: 2020 ident: B37 article-title: Glucagon-like peptide-1 receptor agonists and prevention of stroke systematic review of cardiovascular outcome trials with meta-analysis publication-title: Stroke doi: 10.1161/strokeaha.119.027557 contributor: fullname: Bellastella – volume: 7 start-page: e74 year: 2022 ident: B7 article-title: Primary stroke prevention worldwide: translating evidence into action publication-title: Lancet Public Health doi: 10.1016/s2468-2667(21)00230-9 contributor: fullname: Owolabi – volume: 100 start-page: e422 year: 2023 ident: B3 article-title: Global burden of ischemic stroke in young adults in 204 countries and territories publication-title: Neurology doi: 10.1212/wnl.0000000000201467 contributor: fullname: Zhang – volume: 46 start-page: 101102 year: 2021 ident: B36 article-title: Glp-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art publication-title: Mol Metab doi: 10.1016/j.molmet.2020.101102 contributor: fullname: Nauck – volume: 46 start-page: D1074 year: 2018 ident: B17 article-title: Drugbank 5.0: a major update to the drugbank database for 2018 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkx1037 contributor: fullname: Wishart – volume: 45 start-page: 1184 year: 2022 ident: B16 article-title: Glp-1ras for ischemic stroke prevention in patients with type 2 diabetes without established atherosclerotic cardiovascular disease publication-title: Diabetes Care doi: 10.2337/dc21-1993 contributor: fullname: Yang – volume: 53 start-page: 1300 year: 2021 ident: B21 article-title: Large-scale cis- and trans-eqtl analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression publication-title: Nat Genet doi: 10.1038/s41588-021-00913-z contributor: fullname: Võsa – volume: 130 start-page: 1230 year: 2022 ident: B5 article-title: Advances in acute ischemic stroke therapy publication-title: Circ Res doi: 10.1161/circresaha.121.319948 contributor: fullname: Xiong – volume: 23 start-page: R89 year: 2014 ident: B44 article-title: Mendelian Randomization: genetic anchors for causal inference in epidemiological studies publication-title: Hum Mol Genet doi: 10.1093/hmg/ddu328 contributor: fullname: Davey Smith – year: 2024 ident: B23 article-title: Plasma proteomes and genome-wide association data for causal protein identification in stroke publication-title: Mol Neurobiol doi: 10.1007/s12035-024-04411-1 contributor: fullname: Xu – volume: 175 start-page: Jc26 year: 2022 ident: B13 article-title: In cv disease, glp-1 ras and sglt2 inhibitors reduce cv mortality publication-title: Ann Intern Med doi: 10.7326/j22-0003 contributor: fullname: Kelsey – year: 2024 ident: B33 article-title: Metabolic syndrome and cancer risk: a two-sample Mendelian randomization study of European ancestry publication-title: Int J Surg doi: 10.1097/js9.0000000000001926 contributor: fullname: Zhou – volume: 392 start-page: 1519 year: 2018 ident: B38 article-title: Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial publication-title: Lancet doi: 10.1016/s0140-6736(18)32261-x contributor: fullname: Hernandez – volume: 42 start-page: 259 year: 2022 ident: B6 article-title: Mechanisms of neuronal cell death in ischemic stroke and their therapeutic implications publication-title: Med Res Rev doi: 10.1002/med.21817 contributor: fullname: Tuo – volume: 22 start-page: 57 year: 2023 ident: B14 article-title: Neutral effects of sglt2 inhibitors in acute coronary syndromes, peripheral arterial occlusive disease, or ischemic stroke: a meta-analysis of randomized controlled trials publication-title: Cardiovasc Diabetol doi: 10.1186/s12933-023-01789-5 contributor: fullname: Tsai – volume: 52 start-page: 1545 year: 2021 ident: B15 article-title: Effect of sglt2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: results from the credence trial and meta-analysis publication-title: Stroke doi: 10.1161/strokeaha.120.031623 contributor: fullname: Zhou – volume: 50 start-page: 524 year: 2018 ident: B22 article-title: Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes publication-title: Nat Genet doi: 10.1038/s41588-018-0058-3 contributor: fullname: Malik – volume: 12 year: 2023 ident: B53 article-title: Canagliflozin, an inhibitor of the na(+)-coupled d-glucose cotransporter, sglt2, inhibits astrocyte swelling and brain swelling in cerebral ischemia publication-title: Cells doi: 10.3390/cells12182221 contributor: fullname: Shim – volume: 108 start-page: 25 year: 2021 ident: B48 article-title: Probabilistic colocalization of genetic variants from complex and molecular traits: promise and limitations publication-title: Am J Hum Genet doi: 10.1016/j.ajhg.2020.11.012 contributor: fullname: Hukku – volume: 11 start-page: 3255 year: 2020 ident: B43 article-title: Genetic drug target validation using Mendelian randomisation publication-title: Nat Commun doi: 10.1038/s41467-020-16969-0 contributor: fullname: Schmidt – volume: 40 start-page: 304 year: 2016 ident: B31 article-title: Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator publication-title: Genet Epidemiol doi: 10.1002/gepi.21965 contributor: fullname: Bowden – volume: 121 start-page: e2319811121 year: 2024 ident: B19 article-title: Modeling 0.6 million genes for the rational design of functional cis-regulatory variants and de novo design of cis-regulatory sequences publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.2319811121 contributor: fullname: Li – volume: 44 start-page: 4913 year: 2023 ident: B24 article-title: Mendelian randomization for cardiovascular diseases: principles and applications publication-title: Eur Heart J doi: 10.1093/eurheartj/ehad736 contributor: fullname: Larsson – volume: 30 start-page: 543 year: 2015 ident: B29 article-title: Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors publication-title: Eur J Epidemiol doi: 10.1007/s10654-015-0011-z contributor: fullname: Burgess – volume: 163 start-page: 663 year: 2015 ident: B40 article-title: Effects on clinical outcomes of adding dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitus publication-title: Ann Intern Med doi: 10.7326/m15-0308 contributor: fullname: Ou – volume: 19 start-page: 536 year: 2021 ident: B35 article-title: Hyperglycemia exacerbates ischemic stroke outcome independent of platelet glucose uptake publication-title: J Thromb Haemost doi: 10.1111/jth.15154 contributor: fullname: Denorme – volume: 369 start-page: 1317 year: 2013 ident: B41 article-title: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus publication-title: N Engl J Med doi: 10.1056/NEJMoa1307684 contributor: fullname: Scirica – volume: 4 start-page: 788 year: 2019 ident: B27 article-title: Systolic blood pressure and risk of valvular heart disease: a Mendelian randomization study publication-title: JAMA Cardiol doi: 10.1001/jamacardio.2019.2202 contributor: fullname: Nazarzadeh – volume: 373 start-page: 2247 year: 2015 ident: B39 article-title: Lixisenatide in patients with type 2 diabetes and acute coronary syndrome publication-title: N Engl J Med doi: 10.1056/NEJMoa1509225 contributor: fullname: Pfeffer – volume: 55 start-page: 1866 year: 2023 ident: B20 article-title: Systematic differences in discovery of genetic effects on gene expression and complex traits publication-title: Nat Genet doi: 10.1038/s41588-023-01529-1 contributor: fullname: Mostafavi – volume: 14 start-page: 1232981 year: 2023 ident: B26 article-title: Potential causal association between aspirin use and the reduced risk of hayfever or allergic rhinitis: a Mendelian randomization study publication-title: Front Immunol doi: 10.3389/fimmu.2023.1232981 contributor: fullname: Li – volume: 10 start-page: e1004383 year: 2014 ident: B47 article-title: Bayesian Test for colocalisation between pairs of genetic association studies using summary statistics publication-title: PLoS Genet doi: 10.1371/journal.pgen.1004383 contributor: fullname: Giambartolomei – volume: 51 start-page: 600 year: 2019 ident: B25 article-title: Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases publication-title: Nat Genet doi: 10.1038/s41588-019-0350-x contributor: fullname: Sanna – volume: 21 start-page: 66 year: 2022 ident: B9 article-title: Relationship of cumulative exposure to the triglyceride-glucose index with ischemic stroke: a 9-year prospective study in the kailuan cohort publication-title: Cardiovasc Diabetol doi: 10.1186/s12933-022-01510-y contributor: fullname: Wang – volume: 46 start-page: 1985 year: 2017 ident: B28 article-title: Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption publication-title: Int J Epidemiol doi: 10.1093/ije/dyx102 contributor: fullname: Hartwig – volume: 11 start-page: 15364 year: 2021 ident: B54 article-title: Effects of sglt2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis publication-title: Sci Rep doi: 10.1038/s41598-021-94945-4 contributor: fullname: Tsai – volume: 398 start-page: 262 year: 2021 ident: B12 article-title: Sglt2 inhibitors and glp-1 receptor agonists: established and emerging indications publication-title: Lancet doi: 10.1016/s0140-6736(21)00536-5 contributor: fullname: Brown – volume: 50 start-page: 693 year: 2018 ident: B32 article-title: Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases publication-title: Nat Genet doi: 10.1038/s41588-018-0099-7 contributor: fullname: Verbanck – volume: 148 start-page: 354 year: 2023 ident: B49 article-title: Critical analysis of the effects of sglt2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes publication-title: Circulation doi: 10.1161/circulationaha.123.064346 contributor: fullname: Packer – volume: 13 start-page: 11 year: 2017 ident: B11 article-title: Renal, metabolic and cardiovascular considerations of sglt2 inhibition publication-title: Nat Rev Nephrol doi: 10.1038/nrneph.2016.170 contributor: fullname: DeFronzo – volume: 46 start-page: 2004 year: 2023 ident: B51 article-title: Comparative cardiovascular effectiveness and safety of sglt-2 inhibitors, glp-1 receptor agonists, and dpp-4 inhibitors according to frailty in type 2 diabetes publication-title: Diabetes Care doi: 10.2337/dc23-0671 contributor: fullname: Kutz – volume: 21 start-page: 681 year: 2023 ident: B42 article-title: Genetically proxied antidiabetic drugs targets and stroke risk publication-title: J Transl Med doi: 10.1186/s12967-023-04565-x contributor: fullname: Zhu – volume: 9 start-page: 966708 year: 2022 ident: B52 article-title: Sodium-glucose co-transporter-2 inhibitors reduce the risk of new-onset stroke in patients with type 2 diabetes: a population-based cohort study publication-title: Front Cardiovasc Med doi: 10.3389/fcvm.2022.966708 contributor: fullname: Lin |
| SSID | ssj0001548568 |
| Score | 2.3227386 |
| Snippet | The escalating global economic burden of ischemic stroke poses a significant public health challenge amid global aging trends. The broad therapeutic efficacy... Background The escalating global economic burden of ischemic stroke poses a significant public health challenge amid global aging trends. The broad therapeutic... BackgroundThe escalating global economic burden of ischemic stroke poses a significant public health challenge amid global aging trends. The broad therapeutic... |
| SourceID | doaj pubmedcentral proquest crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 1449185 |
| SubjectTerms | Cardiovascular Medicine DPP-4 inhibitors GLP-1 receptor agonists ischemic stroke Mendelian randomization analysis novel antidiabetic agents SGLT-2 inhibitors |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NT9wwELUqDqgX1EKB0IJcqSekiNhxHLs3WIFWlZYTSNwsO_ZC1DZB-0H_fmfsLNpFSFy42lFizZt4ZjzjN4T8CAJJxEqeS-5FDhaK5Q6Gcm1ZYbkItYtkz5NrOb4Vv-6qu7VWX1gTluiBk-DOCq1kLS1rHDJHKaRR1dpaDpusZWWdeD5ZtRZMpfvBQlVSpTQmRGH6bNo84cVzLjCdqRn2Tl4zRJGv_zUn82Wt5JrxufpEdgavkZ6n1X4mH0K3S7YnQ158j_wb2eUcHpitStse2kc6lGDRrn8KfyhIsE0HrW1D_Wx5P4chT1uIbrE-ns4Xs_53-EltnMxThXjwdIJn5HgWQsGq-f7vcG-TRl7aL-T26vJmNM6Hlgp5w7HGqfa89CGw2pWVR-cIm9SANJQDyy_BeVSu4FZ5WUEoJmTwljnnp7CdTsG3c7rcJ1td34VDQoNXFQBiVWiQQ6-GQEsLHioB26vmhczI6Uq-5jExZxiIOBAMg2AYBMMMYGTkAhF4fhBJr-MAqIIZVMG8pQoZ-b7Cz8BPgpkP24V-OTeggqKK7lRGDhKez58CGagCwrqMqA2kN9ayOdO1D5GIG9-qBBNH77H6r-QjSiSPGa9vZGsxW4ZjcHgW7iTq9n-I6_r- priority: 102 providerName: Directory of Open Access Journals |
| Title | Causal relationship between novel antidiabetic drugs and ischemic stroke: a drug-targeted Mendelian randomization study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39380626 https://www.proquest.com/docview/3114500071/abstract/ https://pubmed.ncbi.nlm.nih.gov/PMC11458414 https://doaj.org/article/098676a1cb96438992299aa2678a1373 |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwEB21PSAuiG_CR2UkTkjpJrbj2NxgRVUhLeJApd4iO_a2Ed1kld0tf58ZJ6l2ESeudqJY8xzPjOf5GeBDkCQiJniquJcpeqg8ddiUGptnlstQuij2vPiuLi7lt6vi6gjUdBYmkvZr15y1t6uztrmJ3Mr1qp5NPLHZj8UcY3j0m7mcHcNxKcRejj6cDZa6UHooYWIGZmbL-o4OnXNJpUyT073Je04oavX_K8D8mye553jOH8OjMWJkn4eRPYGj0D6FB4uxJv4Mfs_tboMP9BOt7aZZs5F-xdruLtwytF4zbLI2NfP97nqDTZ41mNkSN55ttn33K3xiNnamAzs8eLag_XHaB2Ho0Xy3Gs9ssqhJ-xwuz7_-nF-k43UKac2J31R6LnwIeelE4Skwogtq0BraoddXGDhql3GrvSowDZMqeJs755e4lC4xrnNGvICTtmvDK2DB60IKbXWoST-vxCTLSB4KiUur4ZlK4ONk32o9qGZUmG0QGBWBUREY1QhGAl8IgfsHSfA6NnT9dTXCXmVGq1LZvHYkIKZJTdcYazn6WpuLUiTwfsKvwh-Eqh62Dd1uUwmaLTGUSuDlgOf9p9AGOsOULgF9gPTBWA57cE5GEe5pDr7-_1ffwEOyQxprXG_hZNvvwjsMcbbuNG4NnMZ5_QdGXP0M |
| link.rule.ids | 230,315,733,786,790,870,891,2115,27955,27956,53825,53827 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELVKkYBL-SwNn0bihJTdxHEchxusqBZoKg6t6M2yY28btZusdjdF4tcz4yTVbsUFrnaiJJ5x5o3n-ZmQ946jiFjCQsEsDyFCxaGBpjDXcaQZd5nxYs_FsZie8m9n6dkOEcNeGE_aL001qq_mo7q68NzKxbwcDzyx8Y9iAhge4mbMx3fIXZiwLN3I0rvdwVymQnZFTMjB8vGsvMZt54xjMTOP8eTkjTDk1fr_BjFvMyU3Qs_hQ_JzeOmOcXI5atdmVP6-pef471_1iOz1aJR-6vofkx1XPyH3ir7e_pT8muh2BRcsB8rcRbWgPbWL1s21u6JgmapbwK1Kapft-QqaLK0ga0bePV2tl82l-0i17ww75rmztMC1d1xjoRAtbTPv94NSr3f7jJwefjmZTMP-qIawZMidyixLrHNxZpLUIujCw29gnKUBRCEAlEoTMS2tSCHF48JZHRtjZ_CbngFmNHmyT3brpnYHhDorU55ILV2J2nwZJHA5Zy7l8NvOWSQC8mGwnFp0ihwKMhk0s0IzKzSz6s0ckM9o25sLUUzbNzTLc9UPvopyKTKh49KgOJlEpd4815pBHNdxkiUBeTd4hoLJhxUVXbumXakEbeZhWkCed55y8ygYAxlBuhgQueVDW--y3QOe4QW-B0948f-3viX3pyfFkTr6evz9JXmAYxL6Wtorsrtetu41QKm1eePnzR8uvx5J |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb5wwELbaVIp66ftB27Su1FMlFjAGTG7tpqv0sVEOjRSpB8vG3gQlCytYUqm_PjMGot2op1yNEeBvzMx4Pn8m5JPlKCIWMz9lhvvgoSJfQ5OfqyhUjNtMO7Hn-VF6eMJ_nCanA6uyHWiVVaHLSXW5nFTlueNWrpZFMPLEguP5FGJ48JsRD1ZmEdwnD2DSsmwjU-93CHORpKIvZEIelgeL4gq3njOOBc08wtOTN1yRU-z_X5h5my254X5mj8mf8cV71snFpFvrSfHvlqbj3b7sCXk0RKX0S9_nKblnq2dkdz7U3Z-Tv1PVtdChGalz5-WKDhQvWtVX9pICQmW_kFsW1DTdWQtNhpaQPSP_nrbrpr6w-1S5i37PQLeGznENHtdaKHhNUy-HfaHU6d6-ICezb7-nh_5wZINfMORQZYbFxtoo03FiMPjCQ3BgrIWGyCKF4FTokClh0gRSPZ5aoyKtzQJ-1wuIHXUevyQ7VV3Z14RaIxIeCyVsgRp9GSRyOWc24fD7zlmYeuTziJ5c9cocEjIahFoi1BKhlgPUHvmK-N50RFFt11A3Z3IAQIa5SLNURYVGkTKBir15rhQDf66iOIs98nG0DgmTECsrqrJ118oYcXPhmkde9dZy8ygYAxFC2ugRsWVHW--yfQWswwl9j9bw5u63fiC7xwcz-ev70c-35CEOie9Kau_Izrrp7B5EVGv93k2dayGNIMk |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Causal+relationship+between+novel+antidiabetic+drugs+and+ischemic+stroke%3A+a+drug-targeted+Mendelian+randomization+study&rft.jtitle=Frontiers+in+cardiovascular+medicine&rft.au=Zongliang+Yu&rft.au=Zongliang+Yu&rft.au=Xinyi+Liu&rft.au=Xinyi+Liu&rft.date=2024-09-24&rft.pub=Frontiers+Media+S.A&rft.eissn=2297-055X&rft.volume=11&rft_id=info:doi/10.3389%2Ffcvm.2024.1449185&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_098676a1cb96438992299aa2678a1373 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2297-055X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2297-055X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2297-055X&client=summon |